NasdaqGS:MLYSBiotechs
Mineralys Therapeutics (MLYS) Stock Could Be 52% Undervalued After Funding Deal And Lorundrostat Data
Mineralys Therapeutics (MLYS) is in focus after presenting new lorundrostat biomarker data at ENDO 2026 and announcing a US$150 million equity offering along with a US$500 million committed debt facility.
See our latest analysis for Mineralys Therapeutics.
At a latest share price of US$24.63, Mineralys Therapeutics has seen its 30 day share price return fall 17.49%, even as the 1 year total shareholder return is 82.72% and 3 year total shareholder return is 54.42%. This suggests recent...